Navigation Links
AANMA Provides Commentary to FDA Advisory Committees Reviewing Benefit-Risk Assessment of 12 Hour Bronchodilators
Date:12/11/2008

FAIRFAX, Va., Dec. 11 /PRNewswire-USNewswire/ -- Nancy Sander, president and founder of Allergy & Asthma Network Mothers of Asthmatics (AANMA) today urged committee members to preserve patient access to all forms of 12-hour bronchodilators at a joint meeting of the Pulmonary-Allergy Drugs Advisory Committee, Drug Safety and Risk Management Advisory Committee and Pediatric Advisory Committee of the Food and Drug Administration held in Rockville, MD.

Sander also requested the committee use caution in their statements about this issue by avoiding confusing terms such as "rescue" and "controller" to describe affected asthma medications. Patients and prescribers should know these facts:

  • 12-hour bronchodilators are an important add-on therapy to consider when symptoms persist despite use of inhaled corticosteroids.
  • 12-hour bronchodilators used alone or in combination with inhaled corticosteroids does not negate the need to determine the cause of symptoms and eliminate exposures to known allergens and irritants.
  • When using 12-hour bronchodilators, patients should also use inhaled albuterol or inhaled levalbuterol should symptoms occur. The patient should notify the prescribing physician in such circumstances to determine why symptoms are worsening and what actions to take.
  • Albuterol and levalbuterol are frequently and incorrectly called "rescue" medications. They should be used at the first hint of symptoms, not as a last resort as the name implies. 12-hour bronchodilators/inhaled corticosteroids are often and incorrectly called "controller" medications. However, those medications are not indicated to "control" acute symptoms as so many patients incorrectly believe.
  • Making mistakes about when and how to use these two medications can be deadly.

"When prescribed and used as part of a comprehensive treatment plan, 12-hour bronchodilators have given back to patients the ability to work, climb stairs, attend school, sleep through the night, and compete in sports - without symptoms - things most others take for granted," said Sander. "Until policies are in place to ensure that all patients diagnosed with asthma receive care according to the National Asthma Education Prevention Program (NAEPP) guidelines we will continue to see avoidable distress and deaths due to asthma. Patients need asthma care consistent with NAEPP guidelines and patient-centered care free of confusing jargon."

For more information please visit AANMA's Web site at www.breatherville.org. Patients seeking information can also call AANMA's Patient Support Center at 800.315.8056.

About AANMA

Founded in 1985, Allergy & Asthma Network Mothers of Asthmatics is the leading national nonprofit family organization dedicated to eliminating suffering and death due to asthma, allergies and related conditions. AANMA's core areas of expertise are education, advocacy and outreach. Call 800.878.4403 or visit www.breatherville.org.


'/>"/>
SOURCE Allergy & Asthma Network Mothers of Asthmatics
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. AANMA Announces Launch of Free Web-Based Education Program for Patients Transitioning From CFC to HFA Inhalers
2. Study provides hope that some transplant patients could live free of antirejection drugs
3. Study provides hope that some transplant patients could live free of anti-rejection drugs
4. USAID Provides Additional Wildfire Assistance to Greece
5. LifeMasters Provides Tips for Maintaining a Healthy Blood Cholesterol Level
6. New knock-out gene model provides molecular clues to breast cancer
7. PreMD Provides Update on 510(k) Application for PREVU(x) POC
8. SIV infection of natural hosts provides new insights into HIV disease complexity
9. Microarray provides 3 genomic guides to breast cancer treatment decisions
10. Access Innovations Provides Support Services for Agis Network
11. Crdentias VP of Marketing, Christina Hogan, Provides Exclusive Interview on Marketing Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... Jacksonville, Florida (PRWEB) , ... April 27, 2017 , ... ... qualified candidates. But they will rapidly reject an outdated healthcare executive resume. , “If ... good look at your executive resume and wondering if it’s as ready as you ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... North American CAREGiverSM of the Year for her extraordinary compassion and lifelong dedication ... 60,000 North American professional caregivers for the prestigious award each year – identifying ...
(Date:4/27/2017)... ... ... Offering the purest product of its kind, Swissx Labs AG has launched ... the market has seen before. Swissx uses proprietary strains of hemp plants grown in ... for extraction, to produce its CBD oil--maximizing its benefits for health and wellness. Learn ...
(Date:4/26/2017)... ... April 26, 2017 , ... Jump Technologies, Inc., an ... it has completed a round of funding to accelerate its growth strategies. The ... Granite Capital is a growth equity firm focused on investments in healthcare and ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... to announce the ATA 2017 President’s Awards recipients, comprised of organizations and ... healthcare delivery. , The ATA 2017 President’s Awards recognize individuals and ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... CRH) (NYSE MKT: CRHM) (the "Company"), announces that it will participate ... the Sheraton Hotel in Toronto, Ontario . ... is scheduled to present on Tuesday, May 2 at 10:00 am. ... the Board, Tony Holler will also attend the event. ... For more details about the ...
(Date:4/19/2017)... Global Surgical Drainage Device Market: Overview ... remove excess liquid and air. The fluid to be ... lymph. Surgical drains are used in a wide variety ... cardiovascular surgery, neurosurgery, plastic surgery etc. Common use of ... of fluid e.g. blood or pus. Surgical drains are ...
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
Breaking Medicine Technology: